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Jérémie Sellam1,10*†, Elodie Rivière2†, Alice Courties1, Paul-Olivier Rouzaire3, Barbara Tolusso4, Edward M. Vital5,
Paul Emery5, Gianfranco Ferraccioli4, Martin Soubrier6, Bineta Ly2, Houria Hendel Chavez7, Yassine Taoufik7,
Maxime Dougados8 and Xavier Mariette2,9*Erratum
Unfortunately, after publication of this article [1], it was
noticed that the name of Gianfranco Ferraccioli was
incorrectly spelled as Gianfranco Ferraciolli. The corrected
author list can be seen above and the original article has
been updated to correct this error.
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